Concert Pharma (CNCE) Tops Q3 EPS by 6c

Concert Pharma (NASDAQ: CNCE) reported Q3 EPS of ($0.43), $0.06 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $1.67 million.

For earnings history and earnings-related data on Concert Pharma (CNCE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Diana Shipping drops bid for Genco after price demands spike to $36.91